• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于肺癌抗肿瘤药物评估的由癌相关成纤维细胞和人脐静脉内皮细胞组成的3D-3共培养微珠的研制。

Development of a 3D-3 co-culture microbead consisting of cancer-associated fibroblasts and human umbilical vein endothelial cells for the anti-tumor drug assessment of lung cancer.

作者信息

Chen Shuisheng, Chen Wei, Guan Ziyun, Lei Luwen, Lei Yiyan, Tang Kejing, Chen Xiao, Hsu Robert, Dong Yong, Tang Yubo

机构信息

Department of Pharmacy, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.

School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, China.

出版信息

Transl Lung Cancer Res. 2025 Jun 30;14(6):2159-2179. doi: 10.21037/tlcr-2025-525. Epub 2025 Jun 26.

DOI:10.21037/tlcr-2025-525
PMID:40673102
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12261251/
Abstract

BACKGROUND

Drug resistance is a major challenge in the treatment of lung cancer. Increasing evidence indicates that the tumor microenvironment (TME), including cancer-associated fibroblasts (CAFs) and tumor endothelial cells (TECs), plays a significant role in determining the tumor sensitivity to therapeutic agents. There is, however, a dearth of models, two-dimensional (2D) or three-dimensional (3D), that represent the interaction of tumor and stromal components in the TME. The purpose of this study was to use conditionally reprogrammed lung cancer cells (CRLCs), and then use sodium alginate (Alg) and hyaluronic acid (HA) as a hydrogel matrix to establish an 3D model for co-culture of CRLCs, CAFs, and human umbilical vein endothelial cells (HUVECs). The application of this model in the sensitivity testing of anti-tumor drugs and the mechanism of drug resistance were studied, providing new means and ideas for individualized precise anti-tumor treatment and the development of new anti-tumor drugs.

METHODS

We established direct 3D micro-beads of primary lung cancer using conditional reprogramming (CR) technology and co-cultured them with CAFs and HUVECs to evaluate the effect of the TME compartment on tumor sensitivity to chemotherapeutic agents and tyrosine kinase inhibitors (TKIs). RNA sequencing (RNA-seq) was performed on the 3D micro-beads in tissue, mono-culture, and co-culture conditions to uncover transcriptional changes induced by tumor-stroma interaction.

RESULTS

The storage modulus of 3D hydrogel microbeads was shown to be 12 kPa, which is similar to that of lung tumor tissue and demonstrates good biocompatibility, making it suitable for constructing tumor models. RNA-seq data indicated that the co-culture of CAFs and HUVECs can upregulate the pathways related to extracellular matrix (ECM) remodeling, cell adhesion molecules, ECM-receptor interactions, cancer pathways, and the PI3K-Akt signaling pathway. Moreover, the results also showed that after co-culturing CRLCs with CAFs and HUVECs, the cytotoxicity induced by chemotherapeutic agents (cisplatin, paclitaxel, vinorelbine, and gemcitabine) as well as TKIs (gefitinib, afatinib) was reduced. Furthermore, protein expression analysis confirmed that cells seeded on 3D-3 co-culture models significantly overexpressed most of the stemness promoters tested compared to monoculture, including ALDH1A1, NANOG, and SOX9.

CONCLUSIONS

These findings suggest that the patient-derived 3D-3 co-culture model, which highlighted the close association between tumor cell resistance and the TME, offers innovative ideas and methods for addressing treatment resistance in lung cancer patients. By closely mirroring human lung tumors, this model not only enhances our understanding of the disease but also paves the way for the development of more effective and personalized therapeutic strategies.

摘要

背景

耐药性是肺癌治疗中的一项重大挑战。越来越多的证据表明,肿瘤微环境(TME),包括癌症相关成纤维细胞(CAFs)和肿瘤内皮细胞(TECs),在决定肿瘤对治疗药物的敏感性方面起着重要作用。然而,目前缺乏能够代表TME中肿瘤与基质成分相互作用的二维(2D)或三维(3D)模型。本研究的目的是使用条件重编程肺癌细胞(CRLCs),然后以海藻酸钠(Alg)和透明质酸(HA)作为水凝胶基质,建立一种用于CRLCs、CAFs和人脐静脉内皮细胞(HUVECs)共培养的3D模型。研究了该模型在抗肿瘤药物敏感性测试及耐药机制方面的应用,为个体化精准抗肿瘤治疗及新型抗肿瘤药物的研发提供新的手段和思路。

方法

我们利用条件重编程(CR)技术建立原发性肺癌的直接3D微珠,并将其与CAFs和HUVECs共培养,以评估TME区室对肿瘤对化疗药物和酪氨酸激酶抑制剂(TKIs)敏感性的影响。对组织、单培养和共培养条件下的3D微珠进行RNA测序(RNA-seq),以揭示肿瘤-基质相互作用诱导的转录变化。

结果

3D水凝胶微珠的储能模量显示为12 kPa,与肺肿瘤组织相似,具有良好的生物相容性,适合构建肿瘤模型。RNA-seq数据表明,CAFs和HUVECs的共培养可上调与细胞外基质(ECM)重塑、细胞粘附分子、ECM-受体相互作用、癌症通路和PI3K-Akt信号通路相关的途径。此外,结果还表明,将CRLCs与CAFs和HUVECs共培养后,化疗药物(顺铂、紫杉醇、长春瑞滨和吉西他滨)以及TKIs(吉非替尼、阿法替尼)诱导的细胞毒性降低。此外,蛋白质表达分析证实,与单培养相比,接种在3D-3共培养模型上的细胞显著过表达了大多数测试的干性启动子,包括ALDH1A1、NANOG和SOX9。

结论

这些发现表明,患者来源的3D-3共培养模型突出了肿瘤细胞耐药性与TME之间的密切关联,为解决肺癌患者的治疗耐药性提供了创新的思路和方法。通过紧密模拟人类肺肿瘤,该模型不仅增强了我们对该疾病的理解,也为开发更有效和个性化的治疗策略铺平了道路。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9986/12261251/caf44b5de6c4/tlcr-14-06-2159-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9986/12261251/fa0d9b9867e3/tlcr-14-06-2159-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9986/12261251/68993231cb20/tlcr-14-06-2159-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9986/12261251/92f3ab9f7ad7/tlcr-14-06-2159-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9986/12261251/caf44b5de6c4/tlcr-14-06-2159-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9986/12261251/fa0d9b9867e3/tlcr-14-06-2159-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9986/12261251/68993231cb20/tlcr-14-06-2159-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9986/12261251/92f3ab9f7ad7/tlcr-14-06-2159-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9986/12261251/caf44b5de6c4/tlcr-14-06-2159-f4.jpg

相似文献

1
Development of a 3D-3 co-culture microbead consisting of cancer-associated fibroblasts and human umbilical vein endothelial cells for the anti-tumor drug assessment of lung cancer.用于肺癌抗肿瘤药物评估的由癌相关成纤维细胞和人脐静脉内皮细胞组成的3D-3共培养微珠的研制。
Transl Lung Cancer Res. 2025 Jun 30;14(6):2159-2179. doi: 10.21037/tlcr-2025-525. Epub 2025 Jun 26.
2
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.对紫杉醇、多西他赛、吉西他滨和长春瑞滨在非小细胞肺癌中的临床疗效和成本效益进行的快速系统评价。
Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320.
3
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.系统性药理学治疗慢性斑块状银屑病:网络荟萃分析。
Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4.
4
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.慢性斑块状银屑病的全身药理学治疗:一项网状Meta分析。
Cochrane Database Syst Rev. 2020 Jan 9;1(1):CD011535. doi: 10.1002/14651858.CD011535.pub3.
5
The Black Book of Psychotropic Dosing and Monitoring.《精神药物剂量与监测黑皮书》
Psychopharmacol Bull. 2024 Jul 8;54(3):8-59.
6
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.慢性斑块状银屑病的全身药理学治疗:一项网状荟萃分析。
Cochrane Database Syst Rev. 2017 Dec 22;12(12):CD011535. doi: 10.1002/14651858.CD011535.pub2.
7
Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.两种现代生存预测工具 SORG-MLA 和 METSSS 在接受手术联合放疗和单纯放疗治疗有症状长骨转移患者中的比较。
Clin Orthop Relat Res. 2024 Dec 1;482(12):2193-2208. doi: 10.1097/CORR.0000000000003185. Epub 2024 Jul 23.
8
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.拓扑替康治疗卵巢癌的临床有效性和成本效益的快速系统评价。
Health Technol Assess. 2001;5(28):1-110. doi: 10.3310/hta5280.
9
Can a Liquid Biopsy Detect Circulating Tumor DNA With Low-passage Whole-genome Sequencing in Patients With a Sarcoma? A Pilot Evaluation.液体活检能否通过低深度全基因组测序检测肉瘤患者的循环肿瘤DNA?一项初步评估。
Clin Orthop Relat Res. 2025 Jan 1;483(1):39-48. doi: 10.1097/CORR.0000000000003161. Epub 2024 Jun 21.
10
Systemic treatments for metastatic cutaneous melanoma.转移性皮肤黑色素瘤的全身治疗
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.

本文引用的文献

1
Lung cancer organoid-based drug evaluation models and new drug development application trends.基于肺癌类器官的药物评估模型及新药开发应用趋势
Transl Lung Cancer Res. 2024 Dec 31;13(12):3741-3763. doi: 10.21037/tlcr-24-603. Epub 2024 Dec 24.
2
Construction of a lung cancer 3D culture model based on alginate/gelatin micro-beads for drug evaluation.基于海藻酸盐/明胶微珠构建用于药物评估的肺癌3D培养模型。
Transl Lung Cancer Res. 2024 Oct 31;13(10):2698-2712. doi: 10.21037/tlcr-24-490. Epub 2024 Oct 28.
3
Breaking barriers: patient-derived xenograft (PDX) models in lung cancer drug development-are we close to the finish line?
突破障碍:肺癌药物研发中的患者来源异种移植(PDX)模型——我们接近终点了吗?
Transl Lung Cancer Res. 2024 Aug 31;13(8):2098-2102. doi: 10.21037/tlcr-24-206. Epub 2024 Aug 19.
4
Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study.达泊托单抗德卢替康与多西他赛用于既往治疗过的晚期或转移性非小细胞肺癌:随机、开放标签的III期TROPION-Lung01研究
J Clin Oncol. 2025 Jan 20;43(3):260-272. doi: 10.1200/JCO-24-01544. Epub 2024 Sep 9.
5
Promising preclinical patient-derived organoid (PDO) and xenograft (PDX) models in upper gastrointestinal cancers: progress and challenges.在上消化道癌症中具有前景的临床前患者来源的类器官 (PDO) 和异种移植 (PDX) 模型:进展与挑战。
BMC Cancer. 2023 Dec 7;23(1):1205. doi: 10.1186/s12885-023-11434-9.
6
Advances and challenges in the treatment of lung cancer.肺癌治疗的进展与挑战。
Biomed Pharmacother. 2023 Dec 31;169:115891. doi: 10.1016/j.biopha.2023.115891. Epub 2023 Nov 16.
7
Osimertinib with or without Chemotherapy in -Mutated Advanced NSCLC.奥希替尼对比含铂化疗用于 - 突变型晚期 NSCLC。
N Engl J Med. 2023 Nov 23;389(21):1935-1948. doi: 10.1056/NEJMoa2306434. Epub 2023 Nov 8.
8
Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study.Amivantamab 联合化疗加或不加 lazertinib 治疗奥希替尼治疗后进展的 EGFR 突变型晚期 NSCLC:III 期 MARIPOSA-2 研究的主要结果。
Ann Oncol. 2024 Jan;35(1):77-90. doi: 10.1016/j.annonc.2023.10.117. Epub 2023 Oct 23.
9
Define cancer-associated fibroblasts (CAFs) in the tumor microenvironment: new opportunities in cancer immunotherapy and advances in clinical trials.定义肿瘤微环境中的癌症相关成纤维细胞(CAFs):癌症免疫治疗的新机遇和临床试验的进展。
Mol Cancer. 2023 Oct 2;22(1):159. doi: 10.1186/s12943-023-01860-5.
10
HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy.HERTHENA-Lung01 研究:曲妥珠单抗德鲁替康(HER3-DXd)在表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)和铂类化疗治疗后的表皮生长因子受体突变型非小细胞肺癌中的 II 期研究。
J Clin Oncol. 2023 Dec 10;41(35):5363-5375. doi: 10.1200/JCO.23.01476. Epub 2023 Sep 10.